210 related articles for article (PubMed ID: 33866913)
21. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions.
Miller LH; Maxa KL; Winter SS; Gossai NP
Expert Rev Anticancer Ther; 2023; 23(12):1229-1236. PubMed ID: 37850259
[TBL] [Abstract][Full Text] [Related]
22. Management of Nelarabine induced neurotoxicity in a child with T-cell acute lymphoblastic lymphoma.
Karthik U; Motwani J
J Oncol Pharm Pract; 2024 Apr; 30(3):594-596. PubMed ID: 38105625
[TBL] [Abstract][Full Text] [Related]
23. Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.
Commander LA; Seif AE; Insogna IG; Rheingold SR
Br J Haematol; 2010 Aug; 150(3):345-51. PubMed ID: 20528871
[TBL] [Abstract][Full Text] [Related]
24. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
Cohen MH; Johnson JR; Justice R; Pazdur R
Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926
[TBL] [Abstract][Full Text] [Related]
25. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.
Kadia TM; Gandhi V
Expert Rev Hematol; 2017 Jan; 10(1):1-8. PubMed ID: 27869523
[TBL] [Abstract][Full Text] [Related]
26. Nelarabine-associated reversible Guillain-Barré-like syndrome or myelopathy in an adult patient with primary refractory T-lymphoblastic lymphoma.
Lalayanni C; Baldoumi E; Papayiannopoulos S; Tziola K; Saloum R; Anagnostopoulos A
Curr Probl Cancer; 2017; 41(2):138-143. PubMed ID: 28169005
[TBL] [Abstract][Full Text] [Related]
27. Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia.
Fulcher J; Berardi P; Christou G; Villeneuve PJA; Bredeson C; Sabloff M
Leuk Lymphoma; 2021 Sep; 62(9):2295-2297. PubMed ID: 33749497
[No Abstract] [Full Text] [Related]
28. [Severe consciousness disturbance after cord blood transplantation for relapsed T lymphoblastic lymphoma].
Nakamura N; Mizumoto C; Sugimoto A; Fujimoto M; Ayaki T; Takaori-Kondo A
Rinsho Ketsueki; 2024; 65(1):47-51. PubMed ID: 38311389
[TBL] [Abstract][Full Text] [Related]
29. Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine.
Morita K; Jain N; Kantarjian H; Takahashi K; Fang H; Konopleva M; El Hussein S; Wang F; Short NJ; Maiti A; Sasaki K; Garcia-Manero G; Konoplev S; Ravandi F; Khoury JD; Jabbour E
Am J Hematol; 2021 May; 96(5):589-598. PubMed ID: 33639000
[TBL] [Abstract][Full Text] [Related]
30. Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma.
Luskin MR; Ganetsky A; Landsburg DJ; Loren AW; Porter DL; Nasta SD; Svoboda J; Luger SM; Frey NV
Br J Haematol; 2016 Jul; 174(2):332-4. PubMed ID: 26403537
[No Abstract] [Full Text] [Related]
31. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia.
Dunsmore KP; Winter SS; Devidas M; Wood BL; Esiashvili N; Chen Z; Eisenberg N; Briegel N; Hayashi RJ; Gastier-Foster JM; Carroll AJ; Heerema NA; Asselin BL; Rabin KR; Zweidler-Mckay PA; Raetz EA; Loh ML; Schultz KR; Winick NJ; Carroll WL; Hunger SP
J Clin Oncol; 2020 Oct; 38(28):3282-3293. PubMed ID: 32813610
[TBL] [Abstract][Full Text] [Related]
32. Coma associated with nelarabine in an elderly patient with T-cell acute lymphoblastic leukemia and severe chronic renal disease.
Nishijima TF; Shea TC; Wood WA; Voorhees PM; Jamieson K
Leuk Lymphoma; 2016; 57(4):957-60. PubMed ID: 26293208
[No Abstract] [Full Text] [Related]
33. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Frey NV; Luger SM
Blood; 2015 Jul; 126(5):589-96. PubMed ID: 25966988
[TBL] [Abstract][Full Text] [Related]
34. Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy.
Kuhlen M; Bleckmann K; Möricke A; Schrappe M; Vieth S; Escherich G; Bronsema A; Vonalt A; Queudeville M; Zwaan CM; Ebinger M; Debatin KM; Klingebiel T; Koscielniak E; Rossig C; Burkhardt B; Kolb R; Eckert C; Borkhardt A; von Stackelberg A; Chen-Santel C
Br J Haematol; 2017 Oct; 179(2):272-283. PubMed ID: 28771662
[TBL] [Abstract][Full Text] [Related]
35. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Dunsmore KP; Devidas M; Linda SB; Borowitz MJ; Winick N; Hunger SP; Carroll WL; Camitta BM
J Clin Oncol; 2012 Aug; 30(22):2753-9. PubMed ID: 22734022
[TBL] [Abstract][Full Text] [Related]
36. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
[TBL] [Abstract][Full Text] [Related]
37. Nelarabine toxicity in children and adolescents with relapsed/refractory T-ALL/T-LBL: can we avoid throwing the baby out with the bathwater?
Malone A; Smith OP
Br J Haematol; 2017 Oct; 179(2):179-181. PubMed ID: 28891074
[No Abstract] [Full Text] [Related]
38. Nelarabine-induced peripheral and central neurotoxicity: can sequential MRI brain imaging help to define its natural history?
Ewins K; Malone A; Phelan E; Webb D; McHugh JC; Smith O
Br J Haematol; 2017 Oct; 179(2):294-297. PubMed ID: 28961308
[TBL] [Abstract][Full Text] [Related]
39. Pediatric T-ALL complicated by irreversible nelarabine neurotoxicity.
Kanayama T; Imamura T; Nakagawa N; Osone S; Hosoi H
Pediatr Int; 2017 Jul; 59(7):843-845. PubMed ID: 28745456
[No Abstract] [Full Text] [Related]
40. Nelarabine-induced myelopathy in patients undergoing allogeneic hematopoietic cell transplantation: a report of three cases.
Fukuta T; Tanaka T; Hashimoto T; Isahaya K; Kubo Y; Yamano Y; Satomi K; Hiraoka N; Shirakawa N; Arakawa A; Ogawa C; Nishimura N; Aoki J; Ito A; Inamoto Y; Kim SW; Fukuda T
Int J Hematol; 2023 Jun; 117(6):933-940. PubMed ID: 36705847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
